Exabis Library
Welcome to the e-CCO Library!
P527: Body image dissatisfaction is increased in inflammatory bowel disease compared with healthy matched controls but not diseased controls
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P527: Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P527: Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P527: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P527: Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P527: Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P528 Response to biologic therapy in operated Crohn’s disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P528: Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease Patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P528: Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P528: Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P528: Patients’ perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P528: Reducing intravenous monoclonal antibody observation times without compromising patient safety; a single-centre observational study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P529 Natural history and management strategies of ulcerative colitis (UC) in a paediatric population: A 10-year review in a tertiary paediatric gastroenterology centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P529: Adalimumab persistence and its biosimilar in inflammatory bowel disease: experience in a tertiary centre
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P529: Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P529: Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P529: Impact of stress in inflammatory bowel disease. Effect of a group psychological intervention program
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P529: Longer duration of vancomycin prevents recurrence of C. difficile in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P529: Year-two follow-up results of an observational study conducted in Crohn's disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM